Avanos Medical (AVNS) Liabilities and Shareholders Equity (2013 - 2026)

Avanos Medical's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 5.21% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.2 billion (down 24.13% YoY), while the FY2025 annual figure was $1.1 billion, down 6.97% from the prior year.
• Liabilities and Shareholders Equity came in at $1.1 billion for Q1 2026 at Avanos Medical, down from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q2 2025.
• A 5-year average of $1.5 billion and a median of $1.7 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity rose 11.43% in 2022 and tumbled 37.33% in 2025, its largest moves.
• Avanos Medical's Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then declined by 5.29% to $1.7 billion in 2023, then sank by 31.8% to $1.2 billion in 2024, then decreased by 6.97% to $1.1 billion in 2025, then declined by 2.2% to $1.1 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.1 billion, $1.1 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison